Medscape Staff Report Oct. 7, 2002
The U.S. Food and Drug Administration (FDA) and Roche Laboratories have strengthened the safety labeling on Larium (mefloquine hydrochloride) to point out its contraindication in patients with psychiatric disorders.
Larium is used to treat mild to moderate acute malaria caused by mefloquine-susceptible strains of Plasmodium falciparum (both chloroquine-susceptible and resistant strains) or by P. vivax. Lariam is also indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!